Previous researches have reported that ADAMTS9‐AS2 was down‐regulated in colorectal cancer, clear cell renal cell carcinoma, lung cancer and glioma.23, 24, 25, 26, 27 Moreover, ADAMTS9‐AS2 expression was negatively correlated with the survival of these cancers. Here, ADAMTS9-AS2 is linked to clear cell renal carcinoma.